Literature DB >> 33879044

The association between homocysteine levels and cardiovascular disease risk among middle-aged and elderly adults in Taiwan.

Chin-Chuan Shih1, Yu-Lin Shih2, Jau-Yuan Chen3,4.   

Abstract

BACKGROUND: Our study aimed to determine the association between homocysteine levels and cardiovascular disease (CVD) risk in middle-aged and elderly adults in a community in northern Taiwan.
METHODS: Participants in our study included adults aged 50 to 85 years old during community health examinations in 2019. A total of 396 people were enrolled, the ethnicity of all participants is Chinese. We divided participants according to tertiles of ln[homocysteine] level (low, middle and high groups). The CVD risk was calculated by the Framingham cardiovascular risk score (FRS). An FRS ≥ 20% indicated high CVD risk. Pearson correlation coefficients were calculated between homocysteine level and other cardio-metabolic risk factors while adjusting for age. Multivariate logistic regression analysis was used to determine the association of high and middle ln[homocysteine] groups with high CVD risk after adjusting age, sex, uric acid, creatinine, and body mass index (BMI). The Youden index and receiver operating characteristic (ROC) curves were performed to determine the optimized cut-off value.
RESULTS: There were 396 people enrolled for analysis; 41.4% of participants were male, and the average age was 64.79 (± 8.76). In our study, we showed a positive correlation of homocysteine with FRS. In the logistic regression models, higher ln[homocysteine] levels was associated with higher CVD risk with a odds ratio (OR) of 2.499 and 95% confidence interval (CI) of 1.214 to 5.142 in the high homocysteine level group compared with the low homocysteine group after adjusting for traditional CVD risk factors. The area under the ROC curve was 0.667, and a ln[homocysteine] cut-off value of 2.495 µmol/L was determined.
CONCLUSIONS: Middle-aged and elderly people with increased homocysteine levels were associated with higher FRSs in this Taiwan community. Furthermore, homocysteine was an independent risk factor for high CVD risk in this study.

Entities:  

Keywords:  Cardiovascular disease; Framingham risk score; Homocysteine; Middle-aged and elderly

Year:  2021        PMID: 33879044     DOI: 10.1186/s12872-021-02000-x

Source DB:  PubMed          Journal:  BMC Cardiovasc Disord        ISSN: 1471-2261            Impact factor:   2.298


  6 in total

1.  Effect of storage temperature and time on erythrocyte sedimentation rate.

Authors:  Qi-Lei Hu; Zuo-Jie Li; Li Lin; Liang Zhang; Yin-Jiang Lv; Li-Feng Wu; Mei-Yun Chen
Journal:  Eur J Med Res       Date:  2022-05-28       Impact factor: 4.981

2.  Association of Hyperuricemia with 10-Year Atherosclerotic Cardiovascular Disease Risk among Chinese Adults and Elders.

Authors:  Feilong Chen; Li Yuan; Tao Xu; Junting Liu; Shaomei Han
Journal:  Int J Environ Res Public Health       Date:  2022-05-31       Impact factor: 4.614

3.  Predicting the 10-year risk of cardiovascular diseases and its relation to healthy diet indicator in Iranian military personnel.

Authors:  Karim Parastouei; Mojtaba Sepandi; Eslam Eskandari
Journal:  BMC Cardiovasc Disord       Date:  2021-09-05       Impact factor: 2.298

4.  Serum homocysteine is associated with tubular interstitial lesions at the early stage of IgA nephropathy.

Authors:  Zizhen Li; Qianqian Han; Hongbo Ye; Jiajia Li; Xiaona Wei; Rui Zhang; Qiuyan Huang; Yanchun Xu; Guanxian Liu; Bin Li; Qiongqiong Yang
Journal:  BMC Nephrol       Date:  2022-02-23       Impact factor: 2.388

5.  Serum Homocysteine Level Is Positively Correlated With Serum Uric Acid Level in U.S. Adolescents: A Cross Sectional Study.

Authors:  Yumeng Shi; Zuxiang Wu; Ji Wu; Zhiqiang Chen; Ping Li
Journal:  Front Nutr       Date:  2022-03-29

6.  Are there any interactions between modified Nordic-style diet score and MC4R polymorphism on cardiovascular risk factors among overweight and obese women? A cross-sectional study.

Authors:  Dorsa Hosseininasab; Atieh Mirzababaei; Faezeh Abaj; Roya Firoozi; Cain C T Clark; Khadijeh Mirzaei
Journal:  BMC Endocr Disord       Date:  2022-09-01       Impact factor: 3.263

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.